Cue Biopharma (CUE) Assets Average (2018 - 2026)

Cue Biopharma has disclosed Assets Average across 9 years of filings, most recently posting $36.5 million for Q2 2026.

• In Q2 2026, Assets Average rose 15.82% year-over-year to $36.5 million; the TTM figure through Jun 2026 stood at $36.5 million (up 15.82% YoY), while the FY2025 annual figure was $37.2 million, down 20.61% from the prior year.
• Assets Average came in at $36.5 million for Q2 2026 at Cue Biopharma, down from $36.9 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $87.7 million in Q2 2022 to a low of $27.2 million in Q1 2025.
• Average Assets Average over 5 years is $58.6 million, with a median of $57.7 million recorded in 2024.
• Year-over-year, Assets Average tumbled 52.85% in 2025 and increased 15.82% in 2026.
• Over 5 years, Assets Average stood at $83.8 million in 2022, then dropped by 22.18% to $65.2 million in 2023, then slumped by 40.96% to $38.5 million in 2024, then dropped by 4.08% to $36.9 million in 2025, then retreated by 1.27% to $36.5 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $36.5 million in Q2 2026, $36.9 million in Q4 2025, and $36.2 million in Q3 2025.